Sweet nanoparticles trick kidney

February 04, 2020

In the past decade nanomedicine has contributed to better detection and treatment of cancer. Nanoparticles are several 100 times smaller than the smallest grain of sand and can therefore easily travel in the blood stream to reach the tumor. However, they are still too big to be removed by the kidneys. Since several doses of nanoparticles are necessary to treat a tumor, over time the nanoparticles can accumulate in the kidney and cause irreversible damage. In a study published in the scientific journal Biomaterials, materials scientists at the University of Freiburg led by Prof. Dr. Prasad Shastri from the Institute of Macromolecular Chemistry now present a natural solution to this problem: they built nanoparticles with the carbohydrate polysaccharides, which led to the excretion of the particles.

In nature viruses such as the herpes simplex virus-1 and the cytomegalovirus, which are able to pass through the kidney filtration apparatus despite their large size compared to nanoparticles. Shastri and his team identified that both viruses presents sugar molecules on their surface. Inspired by this observation, the scientists engineered nanoparticles containing polysaccharides. These carbohydrates are frequently found in the human tissue environment. Using a real-time imaging technique, which they have established in their laboratory, the team investigated in a mouse model the fate of these nanoparticles. They observed that the polysaccharide-enriched nanoparticles readily pass through the kidney and are excreted with the urine within a few hours after intravenous administration. The decisive factor for the researchers was that the nanoparticles continued to act as intended and were still able to target tumors.

"The ability to combine tumor accumulation and kidney clearance in the same nanoparticle represents a tipping point in ensuring that nanomedicines can be safely administered" says Shastri. "Our nature-inspired approach enabled us to trick the kidney environment to let nanoparticles pass through" adds Dr. Melika Sarem who was a co-author of the study.
-end-
Prasad Shastri is Professor of Biofunctional Macromolecular Chemistry at the Institute for Macromolecular Chemistry and Professor of Cell Signalling Environments in the Excellence Cluster BIOSS Centre for Biological Signalling Studies and at the University of Freiburg.

University of Freiburg

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.